New Frontiers in Osteoporosis Therapy.

@article{Cheng2019NewFI,
  title={New Frontiers in Osteoporosis Therapy.},
  author={Cheng Cheng and Kelly L Wentworth and Dolores M. Shoback},
  journal={Annual review of medicine},
  year={2019}
}
Current osteoporosis medications reduce fractures significantly but have rare and serious adverse effects (osteonecrosis of the jaw, atypical femoral fractures) that may limit their safety for long-term use. Insights from basic bone biology and genetic disorders have led to recent advances in therapeutics for osteoporosis. New approaches now in clinical use include the antisclerostin monoclonal antibody romosozumab, as well as the parathyroid hormone-related peptide analog abaloparatide… 
Recent Progresses in the Treatment of Osteoporosis
TLDR
This review focused on recent progress with regards to the drug development by modification of Wnt pathway, while other pathways/molecules were also discussed briefly.
Combination Therapy of PTH and Antiresorptive Drugs on Osteoporosis: A Review of Treatment Alternatives
TLDR
Combined teriparatide with denosumab appear to show the most substantial and clinically relevant skeletal benefits to osteoporotic patients, and additional research is necessary to define optimal methods of developing sequential and/or cyclical combinations of PTH and antiresorptive agents.
Medical treatment of osteoporosis
  • S. Palacios
  • Medicine
    Climacteric : the journal of the International Menopause Society
  • 2021
TLDR
The combination of antiresorptive and anabolic agents may be useful to increase BMD compared with monotherapy, but more information is warranted to determine the effects on fracture risk.
Pharmacological management of osteoporosis in postmenopausal women: The current state of the art.
  • D. Gatti, A. Fassio
  • Medicine
    Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique
  • 2019
TLDR
The most commonly prescribed antiresorptive drugs, the anabolic agents, the dual-action drugs, and the drugs characterized by an unclear mechanism of action are considered to provide physicians with useful insights for their clinical practice to help identify the secondary forms of osteoporosis.
Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side Effects
TLDR
The aim of this review is to highlight some of the medications that are implicated and other risk factors that can contribute to osteonecrosis of the jaw for myeloma patients, with suggestions for prevention and management.
Osteoporosis and the Potential of Cell-Based Therapeutic Strategies
TLDR
The role that MSCs play in the etiopathology of osteoporosis and their potential use for the treatment of this disease are discussed.
Risk of New Vertebral Fracture and Combination Therapy with Zoledronic Acid and Teriparatide in Diabetic Patients after Percutaneous Kyphoplasty
TLDR
Combination therapy with zoledronic acid and teriparatide could improve the clinical outcomes, and BMD and had the potential to reduce NVF in diabetic patients following PKP.
Comparative efficacy between monoclonal antibodies and conventional drugs in postmenopausal women with osteoporosis: a network meta-analysis.
TLDR
The therapeutic performance of antibody drugs was better than that of the conventional chemical agents, and blosozumab was the best choice (SUCRA 99.2%) to improve lumbar spine BMD.
The Role of Epigenomics in Osteoporosis and Osteoporotic Vertebral Fracture
TLDR
Emerging evidence that epigenetics contributes to the machinery that can alter DNA structure, gene expression, and cellular differentiation during physiological and pathological bone remodeling is reviewed.
...
...